Live Oak Investment Partners acquired a new position in shares of Enovis Co. (NYSE:ENOV - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 24,207 shares of the company's stock, valued at approximately $1,062,000.
Several other institutional investors and hedge funds have also bought and sold shares of the company. UMB Bank n.a. raised its stake in Enovis by 128.2% during the fourth quarter. UMB Bank n.a. now owns 778 shares of the company's stock worth $34,000 after acquiring an additional 437 shares in the last quarter. Pinnacle Bancorp Inc. raised its stake in Enovis by 54.5% during the fourth quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company's stock worth $37,000 after acquiring an additional 300 shares in the last quarter. FMR LLC raised its stake in Enovis by 20.5% during the third quarter. FMR LLC now owns 2,840 shares of the company's stock worth $122,000 after acquiring an additional 484 shares in the last quarter. XTX Topco Ltd acquired a new position in Enovis during the third quarter worth about $217,000. Finally, Legacy Capital Wealth Partners LLC acquired a new position in Enovis during the fourth quarter worth about $228,000. Institutional investors own 98.45% of the company's stock.
Enovis Trading Up 1.6 %
Shares of Enovis stock traded up $0.61 on Friday, hitting $37.71. The stock had a trading volume of 865,559 shares, compared to its average volume of 1,024,392. The stock has a 50 day moving average of $44.06 and a 200 day moving average of $44.04. Enovis Co. has a twelve month low of $35.14 and a twelve month high of $63.51. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.12 and a current ratio of 2.27. The firm has a market capitalization of $2.15 billion, a P/E ratio of -17.22 and a beta of 2.05.
Enovis (NYSE:ENOV - Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The company reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.92 by $0.06. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. The company had revenue of $560.98 million during the quarter, compared to the consensus estimate of $555.14 million. Sell-side analysts expect that Enovis Co. will post 2.79 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Separately, Needham & Company LLC lowered their target price on Enovis from $65.00 to $64.00 and set a "buy" rating for the company in a research note on Thursday, February 27th.
Get Our Latest Report on ENOV
About Enovis
(
Free Report)
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.
Featured Articles
Before you consider Enovis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enovis wasn't on the list.
While Enovis currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
